GlobeNewswire by notified

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Share

Regulated Information - Denominator

Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.

Leuven, BELGIUM, Boston, MA, US – November 3, 2023 – 08.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 77,639,751 new ordinary shares on November 2, 2023, for a total amount of EUR 50,000, as the result of the conversion of 2 convertible bonds, pursuant to the Capital Commitment entered into with Atlas Special Opportunities, LLC.

Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,956,764,011 outstanding ordinary shares carrying voting rights (compared to 2,879,124,260 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.

Therefore, Oxurion publishes the following updated information:

  • Share capital (EUR)
83,006,161.32

  • Total number of securities with voting rights (all ordinary shares)
2,956,764,011
  • Total number of ordinary shares (= denominator)
2,956,764,011
  • Number of outstanding, granted rights to subscribe to securities carrying voting rights not yet issued:
  • 590,500 subscription rights (“SRs”) issued on November 20, 2017, entitling their holders to subscribe to a total number of 590,500 securities carrying voting rights (all ordinary shares);
  • 60,000 SRs issued on December 23, 2020, entitling their holders to subscribe to a total number of 60,000 securities carrying voting rights (all ordinary shares);
  • 972,250 SRs issued on April 14, 2021, entitling their holders to subscribe to a total number of 972,250 securities carrying voting rights (all ordinary shares);
  • 532,500 SRs issued on September 22, 2021, entitling their holders to subscribe to a total number of 532,500 securities carrying voting rights (all ordinary shares);
  • 604,405 SRs issued on December 30, 2021, entitling their holders to subscribe to a total number of 604,405 securities carrying voting rights (all ordinary shares);
  • 272 convertible bonds issued on March 14, 2023, April 20, 2023, May 22, 2023, June 15, 2023, August 10, 2023, September 15, 2023, October 20, 2023, and October 24, 2023, entitling its holder, Atlas Special Opportunities, LLC, to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds pursuant to the Subscription Agreement entered into between the Company and Atlas Special Opportunities, LLC on March 1, 2023, as amended on October 3, 2023.
  • 100 convertible bonds issued on December 20, 2021, entitling their holders (Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company, Kreos Capital VI (UK) Limited, Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P., on November 21, 2021 (as amended from time to time).

END

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV
Tom Graney
Chief Executive Officer
Tel: +32 16 75 13 10
tom.graney@oxurion.com



Michaël Dillen
Chief Business Officer
Tel: +32 16 75 13 10
michael.dillen@oxurion.com
US
Conway Communications
Mary T. Conway
mtconway@conwaycommsir.com





1Press release Oxurion, 02/03/2023

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Zymeworks Announces Participation in Upcoming Investor Conferences27.2.2024 12:00:00 CET | Press release

VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference: Zymeworks’ management will participate in one-on-one meetings and present on March 6th at 11:10 am Eastern Time (ET) in Boston, MA.Barclays 26th Annual Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on March 14th at 11:45 am ET in Miami, FL. All presentations and webcasts will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations. About Zymeworks Inc. Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional bio

Philips launches new Azurion neuro biplane system at #ECR2024 to speed up and improve minimally invasive diagnosis and treatment of neurovascular patients27.2.2024 12:00:00 CET | Press release

February 27, 2024 New image-guided therapy system is a complete interventional solution for confident diagnosis, image guidance, and therapy assessment of patients with stroke or other neurovascular diseases Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced major enhancements to its Image Guided Therapy System – Azurion – with the launch of its new Azurion neuro biplane system. Designed to streamline neurovascular procedures and help care teams make the right decisions faster, treat more patients, and achieve better outcomes, the new interventional system features enhanced 2D and 3D imaging and X-ray detector positioning flexibility. As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare. Minimally invasive procedures enabled by interventional systems like Azurion are a key part of

Millicom (Tigo) Q4 2023 Earnings Release27.2.2024 12:00:00 CET | Press release

Millicom (Tigo) Q4 2023 Earnings Release Luxembourg, February 27, 2024 –Millicom is pleased to announce its fourth quarter 2023 results. Please find below links to the Q4 2023 Earnings Release and IAS 34 Interim Condensed Consolidated Financial Statements. Highlights* Revenue grew 6.8% driven by Service revenue up 7.7%, reflecting the effect of stronger currencies and organic growth of 3.2%, up from 1.8% in Q3 thanks mostly to large B2B contracts in Panama, as well as faster growth in Colombia and Bolivia. Operating profit declined 3.8%, while EBITDA grew 1.6%, and both were impacted by $42 million of one-off severance costs in the quarter. Excluding severance and the benefit of stronger currencies, EBITDA grew 5.3% organically, with Colombia up 24.5%, as margins continued to expand in the country.Operating cash flow was $294 million in Q4 and $1.3 billion for the full year, up 12.3% organically excluding severance and other one-offs thanks largely to improved performance in our Colomb

Jyske Realkredit A/S publishes Supplement no 1 to Base prospectus dated 29 June 202327.2.2024 11:59:13 CET | Press release

To Nasdaq Copenhagen A/S 27 February 2024 Announcement no 20/2024 Jyske Realkredit A/S publishes Supplement no 1 to Base prospectus dated 29 June 2023 Jyske Realkredit hereby publish Supplement no. 1 to Base prospectus dated 29 June 2023 for covered bonds, mortgage bonds and bonds issued pursuant to Section 15 of the Danish Mortage-Credit Loans and Mortgage-Credit Bonds etc. Act. Jyske Realkredit’s Base Prospectus dated 29 June 2023 and Supplements are available for download in Danish and English on Jyske Realkredit’s website www.jyskerealkredit.dk. In the event of discrepancies between the original Danish text and the English translation, the Danish text shall prevail. Jyske Realkredit’s Supplement no 1 is also enclosed this announcement. For more information, please contact: Head of Rating and IR, Christian Bech-Ravn on telephone (+45) 89 89 92 25Legal Counsel Berit Fredberg on telephone (+45) 89 89 79 64 Yours sincerely Jyske Realkredit Søren Winkler Senior Director Attachment 20240

Jyske Realkredit offentliggør tillæg nr. 1 til Basisprospekt27.2.2024 11:59:13 CET | pressemeddelelse

Til Nasdaq Copenhagen A/S 27. februar 2024 Meddelelse nr. 20/2024 Jyske Realkredit offentliggør tillæg nr. 1 til Basisprospekt Jyske Realkredit offentliggør hermed tillæg nr. 1 til Basisprospekt af 29. juni 2023 for Særligt Dækkede Obligationer, Realkreditobligationer og obligationer i medfør af § 15 i lov om realkreditlån og realkreditobligationer (§ 15 obligationer). Jyske Realkredits Basisprospekt af 29. juni 2023 og tillæg er tilgængelige i elektronisk form på dansk og engelsk på Jyske Realkredits hjemmeside www.jyskerealkredit.dk. Ved uoverensstemmelse mellem den danske og den engelske udgave er den danske udgave gældende. Tillæg nr. 1 er desuden vedhæftet denne meddelelse. Spørgsmål vedrørende denne meddelelse kan rettes til: Head of Rating and IR, Christian Bech-Ravn på telefon 89 89 92 25Jurist Berit Fredberg på telefon 89 89 79 64 Venlig hilsen Jyske Realkredit Søren Winkler Områdedirektør Vedhæftet fil 20240227 Tillæg 1 til basisprospekt af 29 juni 2023

HiddenA line styled icon from Orion Icon Library.Eye